Afimmune's Epeleuton shows large decreases in viral load and pathological changes in COVID-19 study
Epeleuton decreases viral titres and SARS-CoV-2 RNA and histopathological damage in the upper and lower respiratory tract Afimmune, a clinical stage drug discovery company focused on the development
United States Kostenloser Wertpapierhandel Mike Sinclair Journal Of The American Heart Association John Climax Business Wire
Source: finanznachrichten.de